Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Matrixyl5 residuesKTTKSEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Pal-KTTKS, Palmitoyl Pentapeptide-4, PPP-4
A five-amino-acid fragment, pulled from the tail end of your own collagen molecule, reduced wrinkle surface area by 68% in a four-month manufacturer trial at just 8 ppm. Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) is a matrikine signal peptide that tells fibroblasts to build new collagen types I, III, and IV. The clinical data comes from small, sponsor-funded studies; no large independent RCT exists. Millions of skincare users apply it twice daily anyway, stacking it with Argireline and GHK-Cu in routines that cost under $10 a month from The Ordinary.
Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS, CAS 214047-00-4) is a synthetic matrikine signaling peptide and one of the most studied topical anti-aging compounds available without a prescription. Sederma reported 68% wrinkle surface area improvement after four months of twice-daily application at 8 ppm. That number comes from a manufacturer study, not an independent trial, so take it with appropriate context. The mechanism is surprisingly elegant. KTTKS is a five-residue sequence (Lys-Thr-Thr-Lys-Ser) copied from the C-terminal propeptide of type I procollagen. When your body processes collagen naturally, it clips off this fragment, and the fragment signals nearby fibroblasts to make more. Matrixyl is that fragment with a palmitic acid chain bolted to the front, giving it enough lipophilicity to cross the stratum corneum. The best independent data is Robinson 2005 [1]: 93 women, 12-week double-blind split-face design, 3 ppm in a basic moisturizer. Wrinkle reduction hit statistical significance by week four on profilometry. A smaller 2023 RCT (n=21, PMC10005804) confirmed it outperformed Acetyl Hexapeptide-3 for crow's feet at eight weeks. Skin permeation is the honest limitation. Choi 2014 [2] tracked Pal-KTTKS through excised skin and found just 0.3 mcg/cm2 reaching the dermis. The rest sits in the stratum corneum and upper epidermis. Whether that dermal fraction is enough to match in vitro collagen stimulation data is an open question. Community adoption is broad. Hundreds of r/SkincareAddiction threads and over 200,000 reviews on the Deciem platform (74% positive) describe gradual smoothing over four to eight weeks. The Ordinary Matrixyl 10% + HA serum at $8.39 per bottle is the benchmark product most users start with.
Collagen production runs on a feedback loop, and Matrixyl hijacks it. When your body synthesizes type I collagen, it processes a larger precursor called procollagen. Enzymes clip off the C-terminal propeptide, releasing a signal fragment that tells fibroblasts to keep producing. KTTKS (residues 196 to 200 of that propeptide) is the active portion of that signal. Attaching a 16-carbon palmitic acid chain to the N-terminus converts it from a water-soluble fragment into something lipophilic enough to cross the stratum corneum. Once Pal-KTTKS reaches dermal fibroblasts, it activates TGF-beta receptor signaling cascades. These cascades upregulate gene transcription for collagen types I, III, and IV. Fibronectin deposition increases. Glycosaminoglycan synthesis, including hyaluronic acid, accelerates. The net structural result: thicker collagen networks that fill in wrinkles from below, more hyaluronic acid holding water in the dermal matrix, and restored fibronectin cross-linking that improves elasticity. In vitro data consistently shows these effects at concentrations matching clinical application levels. Permeation is the bottleneck. Choi 2014 measured skin layer distribution: 4.2 mcg/cm2 stratum corneum, 2.8 mcg/cm2 epidermis, only 0.3 mcg/cm2 dermis. Unmodified KTTKS shows zero measurable retention. The palmitoyl chain is necessary but not sufficient for deep delivery. Liposomal encapsulation [3] is being explored to push more peptide past the epidermal barrier.
Moderate clinical evidence for fine line and surface wrinkle reduction at 3–8 ppm concentration with twice-daily topical application over 12–16 weeks. Key RCT (Robinson 2005, n=93) showed significant wrinkle reduction vs. placebo at 3 ppm. 2023 RCT (n=21) confirmed superiority over Acetyl Hexapeptide-3 for crow's feet at 8 weeks. Primary mechanism (matrikine TGF-β signaling → collagen I, III, HA upregulation) is well-characterized in vitro. All trials are small or manufacturer-sponsored; no large independent RCTs.
Robinson LR et al. (2005; PMID 18492182): 93 Caucasian women aged 35–55, 12-week double-blind split-face RCT; Pal-KTTKS at 3 ppm in oil-in-water moisturizer. Statistically significant wrinkle reduction vs. placebo at 12 weeks; profilometry confirmed measurable fine line improvement at 4 weeks.
All pivotal trials are small (n≤93) and manufacturer-sponsored (Sederma/Croda). No independent large-scale RCTs. Skin permeation data (Choi 2014) shows only 0.3 mcg/cm2 reaches the dermis: mechanistically thin. No head-to-head trial vs. retinoids. Commercial product concentrations (labelled as "10% Matrixyl complex") do not correspond to 10% pure peptide; actual ppm content varies widely.
Broadly positive. Most users report visible skin-smoothing and fine line improvement within 4–8 weeks of twice-daily use. Considered one of the best-tolerated topical peptides: suitable even for retinol-sensitive skin. Results are described as subtle to moderate; no community expectation of injectable-level outcomes.
Both science and community agree that twice-daily topical Matrixyl produces modest fine line reduction over 4–16 weeks, is well-tolerated, and works best for surface wrinkles rather than deep structural lines. Science is more precise about concentration (3–8 ppm pure peptide) while community mostly relies on commercial product concentrations that may deliver considerably less active ingredient than clinical study doses.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2mg | Daily |
| Moderate | 5mg | Daily |
| Aggressive | 10mg | Daily |
Matrixyl is topical. No vials, no reconstitution, no syringes. That alone makes it the easiest peptide in most people's stack. The concentration math trips everyone up. "10% Matrixyl complex" on a label does not mean 10% pure peptide. Actual Pal-KTTKS content in a "10% complex" product sits around 0.003 to 0.005% (3 to 5 ppm). The Robinson RCT used just 3 ppm and still hit significance. So those retail numbers are in the therapeutic range; they're just confusingly labeled. For DIY formulators: dissolve raw Pal-KTTKS powder at 0.0003 to 0.0008% w/v in a water and glycerin base. Target pH 5.5 to 6.5. The palmitoyl ester bond is acid-labile below pH 4. Add 0.5% phenoxyethanol plus 0.5% ethylhexylglycerin for preservation. Refrigerate and use within three months. Apply to clean, dry skin. Wait two to three minutes before layering moisturizer. Twice daily, morning and evening. The non-obvious thing most beginners miss: applying over a heavy cream blocks penetration. Matrixyl goes on bare skin, not on top of your routine.
Apply twice daily for 16 weeks to allow full collagen remodeling cycle. Visible improvement typically begins around week 4 and continues building through week 12-16. A 2-week break is optional: no receptor desensitization has been observed, so continuous long-term use is commonly practiced. Effects are cumulative and diminish gradually over several weeks after discontinuation.
No receptor desensitization, antibody formation, hormonal axis effects, or mandatory safety monitoring interval applies to topical Matrixyl. The 16-week-on / 2-week-off pattern in peptides.ts is derived from the duration of clinical study cycles (Sederma 4-month trials) and the collagen remodeling timeline, not a pharmacological requirement. Continuous long-term use is widely practiced and no adverse effects have been reported in the CIR 2024 safety assessment or any published trial.
Or use the universal Peptide Calculator for any peptide.
Expected: Visible fine line softening and surface smoothing at 4–8 weeks; measurable wrinkle depth reduction at 12–16 weeks. Structural improvement continues through week 16. Deep expression lines and nasolabial folds show slower, partial improvement.
Monitor: Photograph target areas in consistent lighting at baseline and week 4 and 8 to objectively assess responder status. No blood tests required.
Cleanse and fully dry target areas (forehead, crow's feet, nasolabial folds, neck). Matrixyl absorbs best through clean, dry skin with no product residue.
Dispense a pea-sized amount of Matrixyl serum per target zone. For a full face and neck application, two to three pea-sized drops total.
Avoid rubbing or pulling, particularly around the periorbital area where skin is thinnest.
Wait 2 to 3 minutes for absorption before applying the next product in your routine (moisturizer, SPF in the morning).
Layer order: cleanser, then Matrixyl serum, then any other water-based serums (niacinamide, hyaluronic acid), then moisturizer, then SPF (AM only).
Consistency matters more than quantity; the clinical evidence used just 3 ppm twice daily for 12 weeks.
If stacking with Argireline or SNAP-8: apply the expression-line peptide first, let it absorb for 2 minutes, then layer Matrixyl on top. Both target different wrinkle mechanisms.
If stacking with GHK-Cu: separate them to different times of day. GHK-Cu in the evening, Matrixyl in the morning, or vice versa.
Do not apply within 48 hours of chemical peels (glycolic acid above 20%, TCA). Do not apply to broken, actively inflamed, or infected skin.
Store opened serum bottles at 2 to 8 degrees Celsius, away from direct light. Use within 6 months of opening.
N/A: reference route at 3–8 ppm active Pal-KTTKS
All published RCTs used oil-in-water emulsions or water-based serums. In vitro permeation: 14.6% of applied Pal-KTTKS is retained across skin layers (Choi 2014); 4.2 mcg/cm2 stratum corneum, 2.8 mcg/cm2 epidermis, 0.3 mcg/cm2 dermis. Neither KTTKS nor Pal-KTTKS permeates fully through skin into systemic circulation: no injection route exists or is appropriate.
Same nominal active concentration (3–8 ppm), but phosphatidylcholine liposomes or nanostructured lipid carriers increase dermal deposition by 2–5x in ex vivo models. Equivalent clinical outcome improvement not yet established.
PMID 38399273 (Pharmaceutics 2024) describes liposomal encapsulation of Pal-KTTKS: structural and functional characterization confirms improved stability and penetration potential. No commercial liposomal Matrixyl product is widely available as of 2026. DIY liposomal encapsulation is technically complex and not recommended for home formulators.
Standard 3–8 ppm or retail serum applied immediately post-needling (0.25–0.5mm); actual dermal deposition increase over standard topical is not quantified for this peptide specifically
Community-level practice: dermaroller or dermapen followed immediately by serum application while barrier is temporarily permeable. Theoretically increases the 0.3 mcg/cm2 dermis deposition from Choi 2014. Microneedling itself provides independent collagen stimulation via mechanical injury response. Do not apply to compromised, inflamed, or active-acne skin.
Complementary mechanisms: Argireline reduces dynamic expression wrinkles via SNARE complex inhibition; Matrixyl addresses structural collagen loss. Together they cover both functional (muscle movement) and structural (collagen density) wrinkle pathways. The most common multi-peptide anti-aging stack in skincare communities.
Matrixyl AM + Argireline PM; or both AM if separate steps, Argireline first then Matrixyl after absorption
GHK-Cu adds antioxidant, wound-healing, and ECM remodeling activity via a different collagen pathway. Both stimulate fibroblast activity through distinct mechanisms, making them additive for structural anti-aging. Frequently combined in premium anti-aging serums.
Matrixyl AM; GHK-Cu PM; or alternating AM/PM. Avoid mixing in the same step as GHK-Cu may interfere with other actives.
SNAP-8 is the longer-chain variant of Argireline targeting the same SNARE complex. Pairing with Matrixyl provides the same neuromuscular relaxation + collagen synthesis combination with potentially broader SNARE site coverage.
SNAP-8 10% PM; Matrixyl 10% complex AM; or combined in the same multi-peptide serum formulation
Copper tripeptide with tissue-remodeling and collagen-stimulating activity. Community uses alongside Matrixyl for full structural anti-aging coverage; the copper tripeptide mechanism is independent of the matrikine pathway.
AHK-Cu 2x daily concurrent with Matrixyl; both are well-tolerated and pH-compatible
Compromised barrier post-peel alters Pal-KTTKS penetration unpredictably and may cause irritation. Clinical administration guide specifies 48–72 hour minimum wait post-peel before resuming.
Low pH vitamin C formulations may degrade the peptide bond and reduce Matrixyl efficacy. The Ordinary explicitly advises against combining their Matrixyl serum with direct acids and low-pH vitamin C. Use ascorbyl glucoside or ascorbyl tetraisopalmitate as vitamin C alternative for simultaneous application.
Pricing updated 2026-04-09
The biggest concern with Matrixyl is not what it does to your skin. It's what it doesn't reach. Only 0.3 mcg/cm2 of applied Pal-KTTKS penetrates to the dermis (Choi 2014)[2]. The safety profile is clean because systemic absorption is negligible, but that same limited penetration caps the maximum therapeutic effect. Published clinical data: the Robinson 2005 RCT (n=93) reported no increase in skin redness, irritation, or barrier damage versus the vehicle moisturizer alone across 12 weeks. The 2023 RCT (PMC10005804, n=21) confirmed similar tolerability through eight weeks. The CIR Expert Panel (March 2024) evaluated pentapeptide-containing cosmetic ingredients and concluded they are safe as used. Community-reported issues are minimal but worth knowing. Rare mild redness on first application, usually attributed to the serum vehicle (preservatives, alcohol, solvents) rather than the peptide. Allergic contact dermatitis is theoretically possible but unreported at meaningful rates in either clinical data or post-market surveillance. Sticky or tacky texture complaints relate to hyaluronic acid in the formulation base. No systemic side effects are expected or documented. Matrixyl does not permeate through full-thickness skin into circulation. There are no drug interaction concerns at the systemic level. Topical interaction cautions: avoid layering directly over peel-strength AHAs or BHAs (glycolic acid above 20%, TCA peels). Wait 48 to 72 hours post-peel before resuming. Low-pH L-ascorbic acid formulations (below pH 3.5) may hydrolyze the palmitoyl ester bond and reduce peptide activity. The Ordinary specifically advises against combining their Matrixyl serum with direct acids. Contraindications: known allergy to Pal-KTTKS or component amino acids; active skin infections or open wounds at application sites; pregnancy or breastfeeding (no safety data for these populations); children under 18. If you develop persistent redness lasting beyond 24 hours, discontinue and patch-test individual products to isolate the cause. For persistent or worsening skin reactions, consult a dermatologist.
Verify Matrixyl dosing and safety with a second opinion
The Pal-KTTKS ingredient itself is well-characterized, CIR-reviewed (safe as used, March 2024), and stable. Quality risk is medium due to significant formulation transparency issues in the commercial market: many products label "10% Matrixyl complex" or "10% Matrixyl 3000" where the actual pure peptide (Pal-KTTKS) content is typically 0.0003–0.005%: orders of magnitude lower than the claimed percentage implies to consumers. Concentration disclosure practices vary widely, and users may pay premium prices for products with negligible active peptide content.
| Test | When | Target |
|---|---|---|
| Baseline and serial photography (expression lines) | Week 0, Week 4, Week 8, Week 16 | Visible reduction in fine line depth or surface roughness under consistent lighting conditions |
| Skin tolerance patch test | Before first facial application (48-hour patch test on inner arm) | — |
Topical peptide results are subtle and lighting/expression-dependent. Standardized photography (same lighting, same facial expression, same angle) is the only reliable way to objectively assess responder vs. non-responder status and confirm incremental progress.
Contact dermatitis to peptide or vehicle components is rare but possible. Confirms tolerance before full-face use, especially for sensitive or reactive skin types.
No visible changes expected. Matrixyl begins accumulating in the upper skin layers. Some users report a subtle smoothing or hydrating sensation immediately after application due to the serum vehicle.
Early improvements in skin texture and hydration may become noticeable. The peptide is stimulating fibroblast activity and initial collagen synthesis at the dermal level. Fine surface lines may begin to soften.
Measurable wrinkle reduction becomes apparent. Clinical studies report significant fine line improvement by week 4. Skin firmness and elasticity begin to improve as new collagen fibers mature and integrate into the dermal matrix.
Peak results are typically reached in this window. The Sederma clinical trial reported up to 68% wrinkle area improvement at 4 months. Deeper expression lines and nasolabial folds show continued gradual improvement as collagen remodeling progresses.
Effects are not permanent. Wrinkle depth and skin texture gradually return toward baseline over 6-12 weeks after discontinuation as normal collagen turnover resumes without the matrikine stimulus.
Week 1 to 2: Nothing visible happens yet. Pal-KTTKS is distributing across skin layers (about 4.2 mcg/cm2 in the stratum corneum, 2.8 in the epidermis, 0.3 reaching the dermis per Choi 2014). Fibroblast stimulation has started at the cellular level. Some users notice mild hydration or softness, but that's the HA serum vehicle, not the peptide working yet. Keep applying twice daily. Weeks 2 to 4: Collagen gene transcription is ramping up in dermal fibroblasts. Surface texture starts to feel smoother. Fine lines around the eyes may look slightly less defined in the morning. Not everyone sees changes this early; responder status varies. Weeks 4 to 8: This is where the clinical data kicks in. Robinson 2005 picked up statistically significant wrinkle reduction on profilometry at week four (n=93, 3 ppm). The 2023 RCT (PMC10005804) confirmed crow's feet improvement of 0.86 points on the grading scale by week eight. About 74% of Deciem Chatroom users report positive outcomes by this window. Periorbital lines and forehead creases respond first. Weeks 8 to 16: Peak results. Sederma's manufacturer data showed up to 68% wrinkle surface area improvement at four months with 8 ppm twice daily. Collagen matrix is thickening and maturing. Fibronectin cross-linking improves elasticity. Deep expression lines and nasolabial folds show slower, partial improvement compared to fine lines. After stopping: Effects are not permanent. Without the matrikine signal, normal collagen turnover resumes. Wrinkle depth and texture drift back toward baseline over 6 to 12 weeks. No rebound worsening occurs. Resuming the protocol typically restores prior gains within four weeks of consistent re-use.
Pal-KTTKS distributes across skin layers: ~4.2 mcg/cm2 in stratum corneum, 2.8 mcg/cm2 in epidermis, 0.3 mcg/cm2 in dermis (Choi 2014). Fibroblast stimulation has begun but collagen synthesis precedes structural change. No measurable wrinkle change on profilometry.
Most users report no visible skin change. Some note mild hydration or a softer skin texture sensation attributed to the HA serum vehicle rather than the peptide. Consistent twice-daily use is essential through this phase.
Collagen I and III gene transcription is upregulated in dermal fibroblasts. Early glycosaminoglycan and hyaluronic acid production increases. Not yet sufficient new matrix to alter wrinkle depth on imaging at most measurement scales.
Users report subtle skin texture smoothing and improved skin plumpness. Fine lines around eyes may appear slightly less pronounced in morning "rested" skin. Not yet consistent across users at this stage.
Robinson 2005: statistically significant wrinkle reduction measurable by profilometry at 4 weeks (3 ppm, n=93). PMC10005804 (2023): Crow's Feet Grading Scale improved 0.86 points by week 8 for PPP-4 group. New collagen fibers integrating into dermal matrix.
Consistent reports of "wrinkles changed to fine lines" or "lines only visible up close." Periorbital crow's feet and forehead lines most frequently cited as improved. 74% of Deciem Chatroom users report positive outcomes by this window.
Sederma manufacturer data: up to 68% wrinkle surface area improvement at 4 months (8 ppm, twice daily). Collagen matrix thickens and matures; fibronectin cross-linking improves elasticity. Peak measurable benefit window.
Enthusiastic users report continued gradual improvement through week 12–16. Deep expression lines and nasolabial folds show slower, partial improvement. Skin firmness and elasticity noticeably improved.
Matrikine signal withdrawn; normal collagen turnover resumes without stimulus. Wrinkle depth and skin texture return toward baseline over 6–12 weeks as collagen matrix ages and degrades without accelerated new synthesis.
Consistent with clinical expectation: lines gradually re-emerge over 1–2 months. No rebound worsening. Resuming protocol typically restores prior gains within 4 weeks.
Source: No systemic pharmacokinetic data available. Matrixyl is a topical cosmeceutical peptide with minimal transdermal absorption. Skin permeation studies (Choi et al. 2014) show 14.6% of applied Pal-KTTKS is retained across skin layers, but it does not permeate through full-thickness skin into systemic circulation.
Loading the interactive decay curve.
Matrixyl (Palmitoyl Pentapeptide-4) is not FDA-approved for any medical indication. It is classified as a cosmeceutical research ingredient and is available in over-the-counter skincare formulations without a prescription. The Cosmetic Ingredient Review Expert Panel assessed pentapeptide-containing cosmetic ingredients as safe for use in cosmetic formulations (March 2024). Matrixyl is sold as a cosmetic ingredient, not a drug. Marketing claims about wrinkle reduction, collagen stimulation, or anti-aging effects are limited by FTC advertising regulations and cannot imply drug-like therapeutic outcomes. Products are sold "for research purposes" at the raw ingredient level or as cosmetic serums at the consumer level. No WADA restrictions apply. Matrixyl is a topical cosmeceutical with no systemic bioactivity and is not on any prohibited substance list for athletic competition. Regulatory status could shift if manufacturers pursue drug classification for specific dermatological claims, but no such applications are pending as of April 2026. This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any new skincare regimen.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
